Published 15 January 2026 · 10 minutes reading time
Retatrutide is a new triple agonist (GLP-1, GIP, glucagon) showing promising weight-loss results, but it is not yet approved.
Retatrutide targets three receptors and has shown strong weight-loss outcomes in trials. It remains investigational in many markets.
Licensed Physician
Medicinskt granskad: 15 January 2026
Retatrutide is an investigational medication designed to target three metabolic pathways and may deliver substantial weight loss.
By activating GLP-1, GIP, and glucagon receptors, retatrutide aims to improve appetite regulation and energy balance.
The medication is still under clinical investigation and is not yet broadly approved.
Our physicians help you develop a safe and evidence-based plan for medical weight treatment.
Part of Curevo Health
Viktenheten is part of Curevo Health, Sweden’s digital specialist care platform.
